COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences
12/10/2018
NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies
12/10/2018
To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) -- [...]
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
12/10/2018
CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China
12/10/2018
NEW YORK and MELBOURNE, Australia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic [...]
Ossur Hf : Q3 2018 Results - Conference call Thursday 25 October at 11:00 CET
12/10/2018
Announcement no. 60/2018 12 October 2018 Conference call on Thursday 25 October at 11:00 CET / 9:00 GMT / 5:00 EDT Össur will publish its financial results for Q3 2018 prior to market opening on Thursday 25 October. [...]
Fiasp® is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
12/10/2018
Hyderabad, India, 12 October 2018 - For children and adolescents (1 to <18 years old) living with type 1 diabetes, Fiasp ® (an ultra-fast acting formulation of insulin aspart) could be an option to better manage [...]
GUERBET : Mise à disposition du Rapport Financier semestriel 2018
12/10/2018
Villepinte, le 12 octobre 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce ce jour avoir mis à la disposition du public et déposé auprès de [...]
Rule 2.9 Announcement
12/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 October 2018 [...]
Kiadis Pharma provides regulatory and clinical update on ATIR101
12/10/2018
Potential CHMP opinion moved from Q4 2018 into H1 2019 Guidance for initial EU commercial launch in H2 2019 unchanged FDA meeting held under RMAT status Phase 3 study on track with over 20 open sites expected by end [...]
Veritas Pharma Attending CannX International Medical Cannabis Conference in Tel Aviv, Israel
11/10/2018
VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that its CEO Dr. Lui Franciosi and [...]
Abattis Bioceuticals Provides Update on Vaporizer Product Line
11/10/2018
VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to announce an update on our recent product line addition of [...]
Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
11/10/2018
CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products [...]
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
11/10/2018
Global resolution secures patient access to Sandoz biosimilar Hyrimoz ® (adalimumab)[1] for the reference medicine Humira ® ** Resolution paves way for 2018 launch in key European markets and secures US market entry [...]
Align Technology Expands Invisalign Interactive Brand Experience Pilot Program to Connect More Consumers With Invisalign Doctors
11/10/2018
8 New Invisalign Experience Locations in Q4 to Connect Consumers with Invisalign Doctors Designed to Address 300+ Million Consumer Market for Clear Aligner Orthodontics Invisalign Experience Pilot Locations Show [...]
Integra LifeSciences to Host Third Quarter 2018 Earnings Results Conference Call on October 31, 2018
11/10/2018
PLAINSBORO, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2018 financial results on Wednesday, [...]
KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
11/10/2018
Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, [...]
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
11/10/2018
SAN CARLOS, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating [...]
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares
11/10/2018
Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, [...]
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program
11/10/2018
—FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor —FDA [...]

Pages